Literature DB >> 9777981

Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.

B Vergier1, M Beylot-Barry, K Pulford, P Michel, J Bosq, A de Muret, C Beylot, M M Delaunay, M F Avril, S Dalac, C Bodemer, P Joly, A Groppi, A de Mascarel, M Bagot, D Y Mason, J Wechsler, J P Merlio.   

Abstract

Several clinical and histopathologic features of 65 CD30+ cutaneous lymphoproliferations were evaluated for their diagnostic value between CD30+ primary versus secondary cutaneous lymphomas and for their prognostic significance. Primary cutaneous disease, spontaneous regression, and absence of extracutaneous spreading (but not age < or =60 years) were associated with a better prognosis. Epithelial membrane antigen, BNH9, CD15 or CBF.78 antigen were expressed in all types of cutaneous lymphoproliferations. However, epithelial membrane antigen immunoreactivity was more frequently expressed in CD30+ secondary cutaneous large-cell lymphoma. Among CD30+ primary cutaneous large-cell lymphoma, CD15 expression was only seen in localized skin lesions. P53 expression was not associated with spontaneous regression, extracutaneous spreading, or survival. Nested reverse transcriptase-polymerase chain reaction allowed the detection of NPM-ALK transcripts in 10 of 26 CD30+ primary and in 3 of 11 secondary cutaneous large-cell lymphomas. The ALK protein was detected in only 1 of 50 primary and in 4 of 15 secondary cutaneous CD30+ lymphoproliferations. In CD30+ primary cutaneous lymphoproliferation, NPM-ALK transcripts might be expressed by very rare normal or tumoral cells that are undetectable by immunohistochemistry. However, the expression of either NPM-ALK transcripts or ALK-protein was not correlated with prognosis or age in CD30+ cutaneous lymphoproliferations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777981     DOI: 10.1097/00000478-199810000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement.

Authors:  Derek V Chan; Pamela Summers; Marie Tuttle; Kevin D Cooper; Brenda Cooper; Henry Koon; Kord Honda
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

Review 3.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

Review 4.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

Review 5.  Anaplastic Lymphoma Kinase in Cutaneous Malignancies.

Authors:  Severine Cao; Vinod E Nambudiri
Journal:  Cancers (Basel)       Date:  2017-09-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.